

Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis

NCT06531122

Status	RECRUITING
Phase	Phase 3
Sponsor	Kafrelsheikh University
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (5)

- Patients aged 18 and above
- New diagnosis of symptomatic cerebral venous thrombosis as confirmed on CT/CT venogram or MRI/MR venogram
- Ability to randomize within 14 days of neuroimaging-confirmed diagnosis
- The treating clinician is of the opinion that the patient is appropriate for oral anticoagulation as per the standard of care
- The patient or legally authorized representative is able to give written informed consent

Exclusion (10)

- The patient has known antiphospholipid antibody syndrome with a previous history of venous or arterial thrombosis
- The patient is anticipated to require invasive procedures (e.g., lumbar puncture, thrombectomy, hemicraniectomy) prior to initiation of oral anticoagulation
- Patient is unable to swallow due to depressed level of consciousness
- Impaired renal function (i.e., CrCl < 30 mL/min using CockcroftGault equation)
- Pregnancy; if a woman is of childbearing potential a urine or serum beta human chorionic gonadotropin (hCG) test is positive
- ... and 5 more (see full listing online)

Locations (1 total)

Kafr Elsheikh University Hospital, Kafr ash Shaykh, Egypt